The Microbiome as a
Therapeutic Target in
Inflammatory Bowel Disease.
The DFG Research Unit miTarget 5042 brings together an interdisciplinary group of experts in a coordinated programme to specifically study this single economically important and prototypically complex inflammatory disease.
News Show all
5th Doc´s day – first time in Borstel
The 5th Doc´s Day on May 12, 2023, was the third one that we have in person but also the first one that we had the opportunity …read more
Events Show all
Symposium 234: Mucosal Immunology – A Translational View into the Clinic
International Symposium of the RU miTarget
5th Summer School on Microbiome in Health and Disease
CEN 2023: From Data to Knowledge. Advancing Life Sciences.
Patterns of gut microbiome dysbiosis in patients with inflammatory bowel diseases are inconsistent among published studies, probably owing to the heterogeneity of the disease and given the fact that patients enrolled in research studies are often treated and in remission. Therefore, more microbiome studies in “early” (incident) patients that are treatment-naïve and in high-risk individuals are needed. In addition, the microbiome field has to move from association to rather mechanistic studies in order to understand the actual functions and to also prove the associations that serve as hypotheses.
Institute of Clinical Molecular Biology
Prof. Dr. rer. nat. Andre Franke
Fon: +49 (0)431 500-15115
Doctoral qualification programme
Fon: +49 (0)431 500-15113